Home » Medications »
HAMILTON, Bermuda, Jan. 03, 2019 (GLOBE NEWSWIRE) — Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa”), a biopharmaceutical company with a pipeline of five product candidates across […] WILMINGTON, Del.–(BUSINESS WIRE)–Dec. 20, 2018– Incyte (Nasdaq:INCY) today announced that the first patient has been treated in the Phase 3 TRuE-AD clinical trial program evaluating […] The U.S. government told doctors Wednesday to consider prescribing medications that reverse overdoses to many more patients who take opioid painkillers in a move that […]
Kiniksa Announces Active U.S. Investigational New Drug Application for Mavrilimumab
Incyte Announces First Patient Treated in Phase 3 Clinical Trial Program for Ruxolitinib Cream in Atopic Dermatitis
US urges doctors to write more Rx for overdose antidote
Copyright © 2023